Regulation of tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 10, 2010, Pages 5054-5061

  Klocek, Matthew S ^a   Sassani, Joseph W ^a   Donahue, Renee N ^a   Mclaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P21; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; METENKEPHALIN; METHIONINE ENKEPHALIN RECEPTOR; METHIONINE-ENKEPHALIN RECEPTOR; OPIATE RECEPTOR; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; FIBROBLAST; GROWTH INHIBITION; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TENON CAPSULE; TENON CAPSULE FIBROBLAST; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FASCIA; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; GENETICS; METABOLISM; NICK END LABELING; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, METHIONINE; FASCIA; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE SILENCING; IN SITU NICK-END LABELING; MALE; MICROSCOPY, FLUORESCENCE; PROTO-ONCOGENE PROTEINS P21(RAS); RABBITS; RECEPTORS, OPIOID; RNA, SMALL INTERFERING;

EID: 77958145323     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4949     Document Type: Article

References (24)

1. Sherwood MB. A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:478-482.
2. Atreides S-PA. Wound healing modulation in glaucoma filtering surgery. Int Ophthalmol Clinic. 2004;44:61-106.
3. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62:691-699.
4. Chang MR, Cheng Q, Lee DA. Basic science and clinical aspects of wound healing in glaucoma filtering surgery. J Ocul Pharmacol Ther. 1998;14:75-95.
5. Kim TH, Kim SW, Woo JM, et al. Co-treatment of suberoylanilide hydroxamic acid and mitomycin-C induces the apoptosis of rabbit Tenon's capsule fibroblast and improves the outcome of glaucoma filtration surgery. Curr Eye Res. 2008;33:237-245.
6. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-β1, -β2, -β3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci. 2000;41: 756-763.
7. Skuta GL, Parrish RK. Wound healing in glaucoma filtering surgery. Surv Ophthalmol. 1987;32:149-170.
8. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye. 1994;8:11-915.
9. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-346.
10. Mietz H, Welsandt G, Hueber A, Esser C, Krieglstein GK. Synergistic effects of combined cytotoxic and apoptosis-inducing drugs on Tenon's capsule fibroblasts in vitro and in vivo. Graefes Arch Clin Ex Ophthalmol. 2997;245:1367-1375.
11. Naruse S, Yamada J, Hamuro J, Kobayashi T, Mori K, Kinoshita S. AC0576 decreases production of pro-inflammatory chemokine and extracellular matrix by human Tenon's capsule fibroblasts. Exp Eye Res. 2004;79:223-230.
12. Crowston JG, Wang XY, Khaw PT, Zoellner, Healey PR. Human serum reduces mitomycin-C toxicity in human Tenon's fibroblasts. Invest Ophthalmol Vis Sci. 2006;47:946-952.
13. Seong GJ, Park C, Kim CY, et al. Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblasts by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci. 2005;46:3545-3552.
14. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev. 2002;38:351-376.
15. WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Bio Cell. 2009;20:319-327.
16. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor (OGFr) in the regulation of cell proliferation. Exp Biol Med. 2009; 234:532-541.
17. Blebea J, Mazo JE, Kihara TK, et al. Opioid growth factor modulates angiogenesis. J Vasc Surg. 2000;32:364-373.
18. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol. 2009;296:R1716-R1725.
19. Zagon IS, Rahn KA, Bonneau RH, Turel AP, McLaughlin PJ. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res. 2010;1310:154-161.
20. McLaughlin PJ, Park SS, Conway A, Donahue RN, Zagon IS, Goldenberg D. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF): opioid growth factor receptor (OGFr) axis. BMC Cancer. 2009;9:369.
21. Zagon IS, Rhodes RE, McLaughlin PJ. Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat. Cell Tissue Res. 1986;246:561-565.
22. Zagon IS, McLaughlin PJ. Production and characterization of polyclonal and monoclonal antibodies to zeta (ξ) opioid receptor. Brain Res. 1993;630:295-302.
23. Leslie FM. Methods used for the study of opioid receptors. Pharmacol Rev. 1987;39:197-249.
24. Zagon IS, Ruth TB, McLaughlin PJ. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat Rec A Discov Mol Cell Evol Biol. 2005;282:24-37.